Hydrogen Sulfide as Prognostic Factor (H2S-1)

This study is currently recruiting participants.

Verified January 2010 by University Medical Centre Ljubljana

Sponsor:

Information provided by:

University Medical Centre Ljubljana

ClinicalTrials.gov Identifier:

NCT01088490

First received: March 12, 2010

Last updated: March 16, 2010

Last verified: January 2010

History of Changes

Purpose

Hydrogen sulfide (H2S), better known as a poisonous gas, has emerged as the third gaseous transmitter in mammals, next to nitric oxide (NO) and carbon monoxide (CO). Increased production and higher serum concentrations were shown in inflammatory diseases, septic shock and stroke. The investigators will test the hypothesis that higher serum H2S concentrations on admission to intensive care unit (ICU) are linked with higher mortality in patients with shock of any reason.

Condition
Mortality Shock

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Hydrogen Sulfide as Prognostic Factor

Resource links provided by NLM:

MedlinePlus related topics: Shock

U.S. FDA Resources

Further study details as provided by University Medical Centre Ljubljana:

Primary Outcome Measures:

Prognostic value of H2S [ Time Frame: In hospital; ICU mortality 30days ] [ Designated as safety issue: Yes ]
relationship between H2S and mortality of patients during intensive care treatment,

comparison of H2S and lactate prognostic value

Secondary Outcome Measures:

Correlation of H2S with vasopressor requirements [ Time Frame: ICU treatmennt 30days ] [ Designated as safety issue: No ]
relationship between H2S and dose of vasopressors (noradrenaline, epinephrine) used

Estimated Enrollment:	150
Study Start Date:	January 2010
Estimated Study Completion Date:	January 2014
Estimated Primary Completion Date:	January 2012 (Final data collection date for primary outcome measure)

Groups/Cohorts
critically ill Critically ill patients admitted to ICU

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years to 95 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Critically ill patients how are admitted in shock or hemodynamicaly unstable ino intensive care

Criteria

Inclusion Criteria:

shock ( systemic arterial pressure less then 120mmHg, elevated lactate > 2.5mmol/L)

Exclusion Criteria:

patients admitted due to intoxication with H2S

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01088490

Contacts

Contact: Matej Podbregar, MD PhD	+386 49 215960	podbregar.matej@gmail.com
Contact: Tomaž Goslar, MD	+386 41362280	tomaz.goslar@gmail.com

Locations

Slovenia
University Medical Center	Recruiting
Ljubljana, Slovenia, 1000
Contact: Matej Podbregar, MD PhD Podbregar.matej@gmail.com
Contact: Tomaž Goslar, MD +38641362280 tomaz.goslar@gmail.com
Sub-Investigator: Anja Jazbec, MD MSC
Sub-Investigator: Tomaž Goslar, MD
Sub-Investigator: Hugon Možina, MD MSc

Sponsors and Collaborators

University Medical Centre Ljubljana

Investigators

Principal Investigator:

Matej Podbregar, MD PhD

University Medical Centre Ljubljana

More Information

Publications:

?owicka E, Be?towski J. Hydrogen sulfide (H2S) - the third gas of interest for pharmacologists. Pharmacol Rep. 2007 Jan-Feb;59(1):4-24. Review.

Hui Y, Du J, Tang C, Bin G, Jiang H. Changes in arterial hydrogen sulfide (H(2)S) content during septic shock and endotoxin shock in rats. J Infect. 2003 Aug;47(2):155-60.

Mok YY, Atan MS, Yoke Ping C, Zhong Jing W, Bhatia M, Moochhala S, Moore PK. Role of hydrogen sulphide in haemorrhagic shock in the rat: protective effect of inhibitors of hydrogen sulphide biosynthesis. Br J Pharmacol. 2004 Dec;143(7):881-9. Epub 2004 Oct 25.

Li L, Bhatia M, Zhu YZ, Zhu YC, Ramnath RD, Wang ZJ, Anuar FB, Whiteman M, Salto-Tellez M, Moore PK. Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse. FASEB J. 2005 Jul;19(9):1196-8. Epub 2005 Apr 29.

Lawrence NS, Davis J, Compton RG. Analytical strategies for the detection of sulfide: a review. Talanta. 2000 Aug 16;52(5):771-84.

Zhang H, Zhi L, Moore PK, Bhatia M. Role of hydrogen sulfide in cecal ligation and puncture-induced sepsis in the mouse. Am J Physiol Lung Cell Mol Physiol. 2006 Jun;290(6):L1193-201. Epub 2006 Jan 20.

Collin M, Thiemermann C. Hydrogen sulfide and sulfite: novel mediators in the pathophysiology of shock and inflammation. Shock. 2005 Dec;24(6):595-6. No abstract available.

Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci. 1996 Feb 1;16(3):1066-71.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Goslar T, Marš T, Podbregar M. Total plasma sulfide as a marker of shock severity in nonsurgical adult patients. Shock. 2011 Oct;36(4):350-5.

Responsible Party:	Matej Podbregar, UMC Ljubljana
ClinicalTrials.gov Identifier:	NCT01088490 History of Changes
Other Study ID Numbers:	H2S_1
Study First Received:	March 12, 2010
Last Updated:	March 16, 2010
Health Authority:	Slovenia: Ministry of Health

Keywords provided by University Medical Centre Ljubljana:

Hydrogen sulfide
critically ill
mortality

Additional relevant MeSH terms:

Shock
Pathologic Processes

ClinicalTrials.gov processed this record on May 16, 2013

To Top